Applying next-generation sequencing to pancreatic cancer treatment

Nature Reviews Gastroenterology and Hepatology

Volumn 9, Issue 8, 2012, Pages 477-486

  Mardis, Elaine R ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; GEMCITABINE; GENOMIC DNA; GENOMIC RNA; PARAFFIN; SARIDEGIB; SEPRASE;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GENETICS; CANCER IMMUNIZATION; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL ASSESSMENT; DNA FRAGMENTATION; DNA SEQUENCE; EXOME; GENE TECHNOLOGY; GENOME ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN GENOME PROJECT; LASER CAPTURE MICRODISSECTION; MOLECULAR DIAGNOSIS; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; NONHUMAN; PANCREAS CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; RNA SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM; STROMA CELL; SURVIVAL TIME; TISSUE FIXATION;

EXOME; GENOME, HUMAN; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; PANCREATIC NEOPLASMS; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; SEQUENCE ANALYSIS, RNA; STROMAL CELLS; TREATMENT OUTCOME;

EID: 84864859917     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2012.126     Document Type: Review

References (53)

1. National Cancer Institute. Surveillance Epidemiology and End Results [online], http://seer.cancer.gov/csr/ (2012).
2. Koorstra, J.B., Hustinx, S.R., Offerhaus, G.J. & Maitra, A. Pancreatic carcinogenesis. Pancreatology 8, 110-125 (2008). (Pubitemid 351670364)
3. Ghaneh, P., Costello, E. & Neoptolemos, J.P. Biology and management of pancreatic cancer. Gut 56, 1134-1152 (2007). (Pubitemid 47123247)
4. Jemal, A. et al. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225-249 (2009).
5. Fisher, W.E. The promise of a personalized genomic approach to pancreatic cancer and why targeted therapies have missed the mark. World J. Surg. 35, 1766-1769 (2011).
6. Rowley, J.D., Golomb, H.M. & Dougherty, C. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet 1, 549-550 (1977). (Pubitemid 8045927)
7. Rowley, J.D. et al. Further evidence for a non-random chromosomal abnormality in acute promyelocytic leukemia. Int.J. Cancer 20, 869-872 (1977). (Pubitemid 8235944)
8. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 431, 931-945 (2004).
9. Mardis, E.R. A decade's perspective on DNA sequencing technology. Nature 470, 198-203 (2011).
10. Ley, T.J. et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456, 66-72 (2008).
11. Welch, J.S. et al. Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA 305, 1577-1584 (2011).
12. Roychowdhury, S. et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci. Transl. Med. 3, 111ra121 (2011).
13. The Genome Reference Consortium [online], www.ncbi.nlm.nih.gov/projects/ genome/assembly/grc/ (2012).
14. 1000 Genomes. A deep catalog of human genetic variation [online], www.1000genomes.org (2012).
15. Margulies, M. et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature 437, 376-380 (2005). (Pubitemid 41613494)
16. Mardis, E.R. Next-generation DNA sequencing methods. Annu. Rev. Genomics Hum. Genet. 9, 387-402 (2008).
17. Larson, D.E. et al. SomaticSniper: identification of somatic point mutations in whole genome sequencing data. Bioinformatics 28, 311-317 (2012).
18. Chen, K. et al. BreakDancer: an algorithm for high-resolution mapping of genomic structural variation. Nat. Methods 6, 677-681 (2009).
19. Wang, J. et al. CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nat. Methods 8, 652-654 (2011).
20. Koboldt, D.C. et al. VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568-576 (2012).
21. Ding, L. et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481, 506-510 (2012).
22. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.N. Engl.J. Med. 366, 883-892 (2012).
23. Navin, N. et al. Tumour evolution inferred by single-cell sequencing. Nature 472, 90-94 (2011).
24. Albert, T.J. et al. Direct selection of human genomic loci by microarray hybridization. Nat. Methods 4, 903-905 (2007). (Pubitemid 350042375)
25. Hodges, E. et al. Genome-wide in situ exon capture for selective resequencing. Nat. Genet. 39, 1522-1527 (2007). (Pubitemid 350191350)
26. Gnirke, A. et al. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat. Biotechnol. 27, 182-189 (2009).
27. Myers, R.M. et al. A user's guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol. 9, e1001046 (2011).
28. Iorio, M.V. & Croce, C.M. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol. Med. 4, 143-159 (2012).
29. Shah, S.P. et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461, 809-813 (2009).
30. International Cancer Genome Consortium. ICGC cancer genome projects [online], www.icgc.org (2012).
31. National Cancer Institute. The cancer genome atlas [online], http://cancergenome.nih.gov (2012).
32. International Cancer Genome Consortium. Pancreatic cancer-ductal adenocarcinoma [online], http://www.icgc.org/icgc/cgp/68/304/798 (2011).
33. International Cancer Genome Consortium. Rare pancreatic tumors-enteropancreatic endocrine tumors and rare pancreatic exocrine tumors [online], http://www.icgc.org/icgc/cgp/68/427/1221 (2010).
34. Jones, S.J. et al. Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. Genome Biol. 11, R82 (2010).
35. Forbes, S.A. et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39, D945-D950 (2011).
36. Wellcome Trust Sanger Institute. Catalogue of somatic mutations in cancer [online], www.sanger.ac.uk/perl/genetics/CGP/cosmic (2012).
37. Kumar, P., Henikoff, S. & Ng, P.C. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat. Protoc. 4, 1073-1081 (2009).
38. Gonzalez-Perez, A. & Lopez-Bigas, N. Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel. Am.J. Hum. Genet. 88, 440-449 (2011).
39. Dummer, R. & Flaherty, K.T. Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights. Curr. Opin. Oncol. 24, 150-154 (2012).
40. Ding, L. et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464, 999-1005 (2010).
41. Quach, N., Goodman, M.F. & Shibata, D. In vitro mutation artifacts after formalin fixation and error prone translesion synthesis during PCR. BMC Clin. Pathol. 4, 1 (2004).
42. Wilson, R.K. et al. Mutational profiling in the human genome. Cold Spring Harb. Symp. Quant. Biol. 68, 23-29 (2003). (Pubitemid 38955548)
43. Pao, W. et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101, 13306-13311 (2004). (Pubitemid 39209661)
44. Paez, J.G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004). (Pubitemid 38720929)
45. Jones, S. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806 (2008).
46. Yachida, S. et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114-1117 (2010).
47. Campbell, P.J. et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467, 1109-1113 (2010).
48. Haeno, H. et al. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell 148, 362-375 (2012).
49. Hsu, C.C. et al. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann. Surg. Oncol. 17, 981-990 (2010).
50. Artinyan, A., Anaya, D.A., McKenzie, S., Ellenhorn, J.D. & Kim, J. Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma. Cancer 117, 2044-2049 (2011).
51. Mann, K.M. et al. Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc. Natl Acad. Sci. USA 109, 5934-5941 (2012).
52. Olive, K.P. et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457-1461 (2009).
53. Kraman, M. et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 330, 827-830 (2010).